#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


Text=Default mode network deactivation to smoking cue relative to food cue predicts treatment outcome in nicotine use disorder Identifying predictors of treatment outcome for nicotine use disorders (NUD) may help improve efficacy of established treatments, like varenicline.
1-1	0-7	Default	_
1-2	8-12	mode	_
1-3	13-20	network	_
1-4	21-33	deactivation	_
1-5	34-36	to	_
1-6	37-44	smoking	_
1-7	45-48	cue	_
1-8	49-57	relative	_
1-9	58-60	to	_
1-10	61-65	food	_
1-11	66-69	cue	_
1-12	70-78	predicts	_
1-13	79-88	treatment	_
1-14	89-96	outcome	_
1-15	97-99	in	_
1-16	100-108	nicotine	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse
1-17	109-112	use	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse
1-18	113-121	disorder	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse
1-19	122-133	Identifying	_
1-20	134-144	predictors	_
1-21	145-147	of	_
1-22	148-157	treatment	_
1-23	158-165	outcome	_
1-24	166-169	for	_
1-25	170-178	nicotine	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse
1-26	179-182	use	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse
1-27	183-192	disorders	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse
1-28	193-194	(	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse
1-29	195-198	NUD	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse
1-30	199-200	)	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse
1-31	201-204	may	_
1-32	205-209	help	_
1-33	210-217	improve	_
1-34	218-226	efficacy	_
1-35	227-229	of	_
1-36	230-241	established	_
1-37	242-252	treatments	_
1-38	253-254	,	_
1-39	255-259	like	_
1-40	260-271	varenicline	_
1-41	272-273	.	_

Text=Brain reactivity to drug-stimuli predicts relapse risk in nicotine and other substance use disorders in some studies.
2-1	274-279	Brain	_
2-2	280-290	reactivity	_
2-3	291-293	to	_
2-4	294-306	drug-stimuli	_
2-5	307-315	predicts	_
2-6	316-323	relapse	_
2-7	324-328	risk	_
2-8	329-331	in	_
2-9	332-340	nicotine	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse
2-10	341-344	and	_
2-11	345-350	other	_
2-12	351-360	substance	_
2-13	361-364	use	_
2-14	365-374	disorders	_
2-15	375-377	in	_
2-16	378-382	some	_
2-17	383-390	studies	_
2-18	391-392	.	_

Text=Activity in the default mode network (DMN) is affected by drug cues and other palatable cues, but its clinical significance is unclear.
3-1	393-401	Activity	_
3-2	402-404	in	_
3-3	405-408	the	_
3-4	409-416	default	_
3-5	417-421	mode	_
3-6	422-429	network	_
3-7	430-431	(	_
3-8	432-435	DMN	_
3-9	436-437	)	_
3-10	438-440	is	_
3-11	441-449	affected	_
3-12	450-452	by	_
3-13	453-457	drug	_
3-14	458-462	cues	_
3-15	463-466	and	_
3-16	467-472	other	_
3-17	473-482	palatable	_
3-18	483-487	cues	_
3-19	488-489	,	_
3-20	490-493	but	_
3-21	494-497	its	_
3-22	498-506	clinical	_
3-23	507-519	significance	_
3-24	520-522	is	_
3-25	523-530	unclear	_
3-26	531-532	.	_

Text=In this study, 143 individuals with nicotine use disorder (NUD) (male n=91, ages 18–55) received a functional MRI scan during a visual cue task during which they were presented with a series of smoking- or food-related video clips prior to randomization to treatment with varenicline (n=80) or placebo.
4-1	533-535	In	_
4-2	536-540	this	_
4-3	541-546	study	_
4-4	547-548	,	_
4-5	549-552	143	_
4-6	553-564	individuals	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse
4-7	565-569	with	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse
4-8	570-578	nicotine	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse
4-9	579-582	use	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse
4-10	583-591	disorder	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse
4-11	592-593	(	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse
4-12	594-597	NUD	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse
4-13	598-599	)	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse
4-14	600-601	(	_
4-15	602-606	male	_
4-16	607-611	n=91	_
4-17	612-613	,	_
4-18	614-618	ages	_
4-19	619-624	18–55	_
4-20	625-626	)	_
4-21	627-635	received	_
4-22	636-637	a	_
4-23	638-648	functional	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
4-24	649-652	MRI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
4-25	653-657	scan	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
4-26	658-664	during	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
4-27	665-666	a	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
4-28	667-673	visual	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
4-29	674-677	cue	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
4-30	678-682	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
4-31	683-689	during	_
4-32	690-695	which	_
4-33	696-700	they	_
4-34	701-705	were	_
4-35	706-715	presented	_
4-36	716-720	with	_
4-37	721-722	a	_
4-38	723-729	series	_
4-39	730-732	of	_
4-40	733-741	smoking-	_
4-41	742-744	or	_
4-42	745-757	food-related	_
4-43	758-763	video	_
4-44	764-769	clips	_
4-45	770-775	prior	_
4-46	776-778	to	_
4-47	779-792	randomization	_
4-48	793-795	to	_
4-49	796-805	treatment	_
4-50	806-810	with	_
4-51	811-822	varenicline	_
4-52	823-824	(	_
4-53	825-829	n=80	_
4-54	830-831	)	_
4-55	832-834	or	_
4-56	835-842	placebo	_
4-57	843-844	.	_

Text=Group independent components analysis was utilized to isolate the DMN, and temporal sorting was used to calculate the difference between the DMN BOLD signal during smoke versus food cues for each individual.
5-1	845-850	Group	_
5-2	851-862	independent	_
5-3	863-873	components	_
5-4	874-882	analysis	_
5-5	883-886	was	_
5-6	887-895	utilized	_
5-7	896-898	to	_
5-8	899-906	isolate	_
5-9	907-910	the	_
5-10	911-914	DMN	_
5-11	915-916	,	_
5-12	917-920	and	_
5-13	921-929	temporal	_
5-14	930-937	sorting	_
5-15	938-941	was	_
5-16	942-946	used	_
5-17	947-949	to	_
5-18	950-959	calculate	_
5-19	960-963	the	_
5-20	964-974	difference	_
5-21	975-982	between	_
5-22	983-986	the	_
5-23	987-990	DMN	_
5-24	991-995	BOLD	_
5-25	996-1002	signal	_
5-26	1003-1009	during	_
5-27	1010-1015	smoke	_
5-28	1016-1022	versus	_
5-29	1023-1027	food	_
5-30	1028-1032	cues	_
5-31	1033-1036	for	_
5-32	1037-1041	each	_
5-33	1042-1052	individual	_
5-34	1053-1054	.	_

Text=Food cues were associated with greater deactivation compared to smoke cues in the DMN.
6-1	1055-1059	Food	_
6-2	1060-1064	cues	_
6-3	1065-1069	were	_
6-4	1070-1080	associated	_
6-5	1081-1085	with	_
6-6	1086-1093	greater	_
6-7	1094-1106	deactivation	_
6-8	1107-1115	compared	_
6-9	1116-1118	to	_
6-10	1119-1124	smoke	_
6-11	1125-1129	cues	_
6-12	1130-1132	in	_
6-13	1133-1136	the	_
6-14	1137-1140	DMN	_
6-15	1141-1142	.	_

Text=Correcting for baseline smoking and other clinical variables which have been shown to be related to treatment outcome in previous work, a less positive Smoke-Food difference score predicted greater smoking at 6 and 12 weeks when both treatment groups were combined (p=0.005, beta=−0.766).
7-1	1143-1153	Correcting	_
7-2	1154-1157	for	_
7-3	1158-1166	baseline	_
7-4	1167-1174	smoking	_
7-5	1175-1178	and	_
7-6	1179-1184	other	_
7-7	1185-1193	clinical	_
7-8	1194-1203	variables	_
7-9	1204-1209	which	_
7-10	1210-1214	have	_
7-11	1215-1219	been	_
7-12	1220-1225	shown	_
7-13	1226-1228	to	_
7-14	1229-1231	be	_
7-15	1232-1239	related	_
7-16	1240-1242	to	_
7-17	1243-1252	treatment	_
7-18	1253-1260	outcome	_
7-19	1261-1263	in	_
7-20	1264-1272	previous	_
7-21	1273-1277	work	_
7-22	1278-1279	,	_
7-23	1280-1281	a	_
7-24	1282-1286	less	_
7-25	1287-1295	positive	_
7-26	1296-1306	Smoke-Food	_
7-27	1307-1317	difference	_
7-28	1318-1323	score	_
7-29	1324-1333	predicted	_
7-30	1334-1341	greater	_
7-31	1342-1349	smoking	_
7-32	1350-1352	at	_
7-33	1353-1354	6	_
7-34	1355-1358	and	_
7-35	1359-1361	12	_
7-36	1362-1367	weeks	_
7-37	1368-1372	when	_
7-38	1373-1377	both	_
7-39	1378-1387	treatment	_
7-40	1388-1394	groups	_
7-41	1395-1399	were	_
7-42	1400-1408	combined	_
7-43	1409-1410	(	_
7-44	1411-1418	p=0.005	_
7-45	1419-1420	,	_
7-46	1421-1432	beta=−0.766	_
7-47	1433-1434	)	_
7-48	1435-1436	.	_

Text=An exploratory analysis of executive control (ECN) and salience networks demonstrated that a more positive Smoke-Food difference score for ECN predicted a more robust response to varenicline relative to placebo.
8-1	1437-1439	An	_
8-2	1440-1451	exploratory	_
8-3	1452-1460	analysis	_
8-4	1461-1463	of	_
8-5	1464-1473	executive	_
8-6	1474-1481	control	_
8-7	1482-1483	(	_
8-8	1484-1487	ECN	_
8-9	1488-1489	)	_
8-10	1490-1493	and	_
8-11	1494-1502	salience	_
8-12	1503-1511	networks	_
8-13	1512-1524	demonstrated	_
8-14	1525-1529	that	_
8-15	1530-1531	a	_
8-16	1532-1536	more	_
8-17	1537-1545	positive	_
8-18	1546-1556	Smoke-Food	_
8-19	1557-1567	difference	_
8-20	1568-1573	score	_
8-21	1574-1577	for	_
8-22	1578-1581	ECN	_
8-23	1582-1591	predicted	_
8-24	1592-1593	a	_
8-25	1594-1598	more	_
8-26	1599-1605	robust	_
8-27	1606-1614	response	_
8-28	1615-1617	to	_
8-29	1618-1629	varenicline	_
8-30	1630-1638	relative	_
8-31	1639-1641	to	_
8-32	1642-1649	placebo	_
8-33	1650-1651	.	_

Text=These findings provide further support to theories that brain reactivity to palatable cues, and in particular in DMN, may have direct clinical relevance in NUD.
9-1	1652-1657	These	_
9-2	1658-1666	findings	_
9-3	1667-1674	provide	_
9-4	1675-1682	further	_
9-5	1683-1690	support	_
9-6	1691-1693	to	_
9-7	1694-1702	theories	_
9-8	1703-1707	that	_
9-9	1708-1713	brain	_
9-10	1714-1724	reactivity	_
9-11	1725-1727	to	_
9-12	1728-1737	palatable	_
9-13	1738-1742	cues	_
9-14	1743-1744	,	_
9-15	1745-1748	and	_
9-16	1749-1751	in	_
9-17	1752-1762	particular	_
9-18	1763-1765	in	_
9-19	1766-1769	DMN	_
9-20	1770-1771	,	_
9-21	1772-1775	may	_
9-22	1776-1780	have	_
9-23	1781-1787	direct	_
9-24	1788-1796	clinical	_
9-25	1797-1806	relevance	_
9-26	1807-1809	in	_
9-27	1810-1813	NUD	_
9-28	1814-1815	.	_

Text=Patients and Methods Subjects Subjects were treatment-seeking cigarette smokers between the ages of 18 and 55recruited and enrolled in a randomized, double-blind, placebo-controlled trial of varenicline which was designed to identify biomarkers of effectiveness [manuscript summarizing clinical results, under review].
10-1	1816-1824	Patients	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
10-2	1825-1828	and	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
10-3	1829-1836	Methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
10-4	1837-1845	Subjects	_
10-5	1846-1854	Subjects	_
10-6	1855-1859	were	_
10-7	1860-1877	treatment-seeking	_
10-8	1878-1887	cigarette	_
10-9	1888-1895	smokers	http://maven.renci.org/NeuroBridge/neurobridge#Person
10-10	1896-1903	between	_
10-11	1904-1907	the	_
10-12	1908-1912	ages	_
10-13	1913-1915	of	_
10-14	1916-1918	18	_
10-15	1919-1922	and	_
10-16	1923-1934	55recruited	_
10-17	1935-1938	and	_
10-18	1939-1947	enrolled	_
10-19	1948-1950	in	_
10-20	1951-1952	a	_
10-21	1953-1963	randomized	_
10-22	1964-1965	,	_
10-23	1966-1978	double-blind	_
10-24	1979-1980	,	_
10-25	1981-1999	placebo-controlled	_
10-26	2000-2005	trial	_
10-27	2006-2008	of	_
10-28	2009-2020	varenicline	_
10-29	2021-2026	which	_
10-30	2027-2030	was	_
10-31	2031-2039	designed	_
10-32	2040-2042	to	_
10-33	2043-2051	identify	_
10-34	2052-2062	biomarkers	_
10-35	2063-2065	of	_
10-36	2066-2079	effectiveness	_
10-37	2080-2081	[	_
10-38	2082-2092	manuscript	_
10-39	2093-2104	summarizing	_
10-40	2105-2113	clinical	_
10-41	2114-2121	results	_
10-42	2122-2123	,	_
10-43	2124-2129	under	_
10-44	2130-2136	review	_
10-45	2137-2138	]	_
10-46	2139-2140	.	_

Text=Individuals were required to smoke at least 10 cigarettes per day and to have not previously taken varenicline.
11-1	2141-2152	Individuals	_
11-2	2153-2157	were	_
11-3	2158-2166	required	_
11-4	2167-2169	to	_
11-5	2170-2175	smoke	_
11-6	2176-2178	at	_
11-7	2179-2184	least	_
11-8	2185-2187	10	_
11-9	2188-2198	cigarettes	_
11-10	2199-2202	per	_
11-11	2203-2206	day	_
11-12	2207-2210	and	_
11-13	2211-2213	to	_
11-14	2214-2218	have	_
11-15	2219-2222	not	_
11-16	2223-2233	previously	_
11-17	2234-2239	taken	_
11-18	2240-2251	varenicline	_
11-19	2252-2253	.	_

Text=Participants were excluded for current pregnancy/nursing, use of illicit drugs (excluding marijuana) in the past 60 days (confirmed by urine toxicology screen), serious health concerns (cardiovascular disease, uncontrolled hypertension, hepatic or renal disease, diabetes), or for meeting DSM-IV criteria for psychotic, bipolar, or major depressive disorder in the past year.
12-1	2254-2266	Participants	_
12-2	2267-2271	were	_
12-3	2272-2280	excluded	_
12-4	2281-2284	for	_
12-5	2285-2292	current	_
12-6	2293-2310	pregnancy/nursing	_
12-7	2311-2312	,	_
12-8	2313-2316	use	_
12-9	2317-2319	of	_
12-10	2320-2327	illicit	_
12-11	2328-2333	drugs	_
12-12	2334-2335	(	_
12-13	2336-2345	excluding	_
12-14	2346-2355	marijuana	_
12-15	2356-2357	)	_
12-16	2358-2360	in	_
12-17	2361-2364	the	_
12-18	2365-2369	past	_
12-19	2370-2372	60	_
12-20	2373-2377	days	_
12-21	2378-2379	(	_
12-22	2380-2389	confirmed	_
12-23	2390-2392	by	_
12-24	2393-2398	urine	_
12-25	2399-2409	toxicology	_
12-26	2410-2416	screen	_
12-27	2417-2418	)	_
12-28	2419-2420	,	_
12-29	2421-2428	serious	_
12-30	2429-2435	health	_
12-31	2436-2444	concerns	_
12-32	2445-2446	(	_
12-33	2447-2461	cardiovascular	_
12-34	2462-2469	disease	_
12-35	2470-2471	,	_
12-36	2472-2484	uncontrolled	_
12-37	2485-2497	hypertension	_
12-38	2498-2499	,	_
12-39	2500-2507	hepatic	_
12-40	2508-2510	or	_
12-41	2511-2516	renal	_
12-42	2517-2524	disease	_
12-43	2525-2526	,	_
12-44	2527-2535	diabetes	_
12-45	2536-2537	)	_
12-46	2538-2539	,	_
12-47	2540-2542	or	_
12-48	2543-2546	for	_
12-49	2547-2554	meeting	_
12-50	2555-2561	DSM-IV	_
12-51	2562-2570	criteria	_
12-52	2571-2574	for	_
12-53	2575-2584	psychotic	_
12-54	2585-2586	,	_
12-55	2587-2594	bipolar	_
12-56	2595-2596	,	_
12-57	2597-2599	or	_
12-58	2600-2605	major	_
12-59	2606-2616	depressive	_
12-60	2617-2625	disorder	_
12-61	2626-2628	in	_
12-62	2629-2632	the	_
12-63	2633-2637	past	_
12-64	2638-2642	year	_
12-65	2643-2644	.	_

Text=205 individuals were randomized using an urn randomization technique, and treated for 12 weeks.
13-1	2645-2648	205	_
13-2	2649-2660	individuals	_
13-3	2661-2665	were	_
13-4	2666-2676	randomized	_
13-5	2677-2682	using	_
13-6	2683-2685	an	_
13-7	2686-2689	urn	_
13-8	2690-2703	randomization	_
13-9	2704-2713	technique	_
13-10	2714-2715	,	_
13-11	2716-2719	and	_
13-12	2720-2727	treated	_
13-13	2728-2731	for	_
13-14	2732-2734	12	_
13-15	2735-2740	weeks	_
13-16	2741-2742	.	_

Text=Of these, 143 underwent a cue-exposure task during fMRI prior to medication initiation (male n=91; varenicline n=80; mean age 34.05 yrs, SD 10.16), and their data were used for the analyses that follow; individuals who chose not to have an MRI or had exclusions for MRI were still enrolled in the clinical trial.
14-1	2743-2745	Of	_
14-2	2746-2751	these	_
14-3	2752-2753	,	_
14-4	2754-2757	143	_
14-5	2758-2767	underwent	_
14-6	2768-2769	a	_
14-7	2770-2782	cue-exposure	_
14-8	2783-2787	task	_
14-9	2788-2794	during	_
14-10	2795-2799	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
14-11	2800-2805	prior	_
14-12	2806-2808	to	_
14-13	2809-2819	medication	_
14-14	2820-2830	initiation	_
14-15	2831-2832	(	_
14-16	2833-2837	male	_
14-17	2838-2842	n=91	_
14-18	2843-2844	;	_
14-19	2845-2856	varenicline	_
14-20	2857-2861	n=80	_
14-21	2862-2863	;	_
14-22	2864-2868	mean	_
14-23	2869-2872	age	_
14-24	2873-2878	34.05	_
14-25	2879-2882	yrs	_
14-26	2883-2884	,	_
14-27	2885-2887	SD	_
14-28	2888-2893	10.16	_
14-29	2894-2895	)	_
14-30	2896-2897	,	_
14-31	2898-2901	and	_
14-32	2902-2907	their	_
14-33	2908-2912	data	_
14-34	2913-2917	were	_
14-35	2918-2922	used	_
14-36	2923-2926	for	_
14-37	2927-2930	the	_
14-38	2931-2939	analyses	_
14-39	2940-2944	that	_
14-40	2945-2951	follow	_
14-41	2952-2953	;	_
14-42	2954-2965	individuals	_
14-43	2966-2969	who	_
14-44	2970-2975	chose	_
14-45	2976-2979	not	_
14-46	2980-2982	to	_
14-47	2983-2987	have	_
14-48	2988-2990	an	_
14-49	2991-2994	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
14-50	2995-2997	or	_
14-51	2998-3001	had	_
14-52	3002-3012	exclusions	_
14-53	3013-3016	for	_
14-54	3017-3020	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
14-55	3021-3025	were	_
14-56	3026-3031	still	_
14-57	3032-3040	enrolled	_
14-58	3041-3043	in	_
14-59	3044-3047	the	_
14-60	3048-3056	clinical	_
14-61	3057-3062	trial	_
14-62	3063-3064	.	_

Text=Clinical Trial Design Consistent with previous trials patients were titrated to 1mg twice daily as follows: days 1–3, 0.5 mg per day; days 4–7, 0.5 mg twice per day, and after day 7, 1 mg twice per day.
15-1	3065-3073	Clinical	_
15-2	3074-3079	Trial	_
15-3	3080-3086	Design	_
15-4	3087-3097	Consistent	_
15-5	3098-3102	with	_
15-6	3103-3111	previous	_
15-7	3112-3118	trials	_
15-8	3119-3127	patients	_
15-9	3128-3132	were	_
15-10	3133-3141	titrated	_
15-11	3142-3144	to	_
15-12	3145-3148	1mg	_
15-13	3149-3154	twice	_
15-14	3155-3160	daily	_
15-15	3161-3163	as	_
15-16	3164-3171	follows	_
15-17	3172-3173	:	_
15-18	3174-3178	days	_
15-19	3179-3182	1–3	_
15-20	3183-3184	,	_
15-21	3185-3188	0.5	_
15-22	3189-3191	mg	_
15-23	3192-3195	per	_
15-24	3196-3199	day	_
15-25	3200-3201	;	_
15-26	3202-3206	days	_
15-27	3207-3210	4–7	_
15-28	3211-3212	,	_
15-29	3213-3216	0.5	_
15-30	3217-3219	mg	_
15-31	3220-3225	twice	_
15-32	3226-3229	per	_
15-33	3230-3233	day	_
15-34	3234-3235	,	_
15-35	3236-3239	and	_
15-36	3240-3245	after	_
15-37	3246-3249	day	_
15-38	3250-3251	7	_
15-39	3252-3253	,	_
15-40	3254-3255	1	_
15-41	3256-3258	mg	_
15-42	3259-3264	twice	_
15-43	3265-3268	per	_
15-44	3269-3272	day	_
15-45	3273-3274	.	_

Text=All participants received a 30 minute baseline motivational enhancement session during which a target quit date was set for day 8, and brief (10 minute) counseling visits with their assigned therapist at each assessment (2, 6, 12 weeks).
16-1	3275-3278	All	_
16-2	3279-3291	participants	_
16-3	3292-3300	received	_
16-4	3301-3302	a	_
16-5	3303-3305	30	_
16-6	3306-3312	minute	_
16-7	3313-3321	baseline	_
16-8	3322-3334	motivational	_
16-9	3335-3346	enhancement	_
16-10	3347-3354	session	_
16-11	3355-3361	during	_
16-12	3362-3367	which	_
16-13	3368-3369	a	_
16-14	3370-3376	target	_
16-15	3377-3381	quit	_
16-16	3382-3386	date	_
16-17	3387-3390	was	_
16-18	3391-3394	set	_
16-19	3395-3398	for	_
16-20	3399-3402	day	_
16-21	3403-3404	8	_
16-22	3405-3406	,	_
16-23	3407-3410	and	_
16-24	3411-3416	brief	_
16-25	3417-3418	(	_
16-26	3419-3421	10	_
16-27	3422-3428	minute	_
16-28	3429-3430	)	_
16-29	3431-3441	counseling	_
16-30	3442-3448	visits	_
16-31	3449-3453	with	_
16-32	3454-3459	their	_
16-33	3460-3468	assigned	_
16-34	3469-3478	therapist	_
16-35	3479-3481	at	_
16-36	3482-3486	each	_
16-37	3487-3497	assessment	_
16-38	3498-3499	(	_
16-39	3500-3501	2	_
16-40	3502-3503	,	_
16-41	3504-3505	6	_
16-42	3506-3507	,	_
16-43	3508-3510	12	_
16-44	3511-3516	weeks	_
16-45	3517-3518	)	_
16-46	3519-3520	.	_

Text=Clinical Assessments A battery of assessments were obtained at screen, baseline, 2, 6 and 12 weeks.
17-1	3521-3529	Clinical	_
17-2	3530-3541	Assessments	_
17-3	3542-3543	A	_
17-4	3544-3551	battery	_
17-5	3552-3554	of	_
17-6	3555-3566	assessments	_
17-7	3567-3571	were	_
17-8	3572-3580	obtained	_
17-9	3581-3583	at	_
17-10	3584-3590	screen	_
17-11	3591-3592	,	_
17-12	3593-3601	baseline	_
17-13	3602-3603	,	_
17-14	3604-3605	2	_
17-15	3606-3607	,	_
17-16	3608-3609	6	_
17-17	3610-3613	and	_
17-18	3614-3616	12	_
17-19	3617-3622	weeks	_
17-20	3623-3624	.	_

Text=Only measures relevant to this study are summarized below; a full description of the clinical assessment measures is provided in the clinical outcomes paper.
18-1	3625-3629	Only	_
18-2	3630-3638	measures	_
18-3	3639-3647	relevant	_
18-4	3648-3650	to	_
18-5	3651-3655	this	_
18-6	3656-3661	study	_
18-7	3662-3665	are	_
18-8	3666-3676	summarized	_
18-9	3677-3682	below	_
18-10	3683-3684	;	_
18-11	3685-3686	a	_
18-12	3687-3691	full	_
18-13	3692-3703	description	_
18-14	3704-3706	of	_
18-15	3707-3710	the	_
18-16	3711-3719	clinical	_
18-17	3720-3730	assessment	_
18-18	3731-3739	measures	_
18-19	3740-3742	is	_
18-20	3743-3751	provided	_
18-21	3752-3754	in	_
18-22	3755-3758	the	_
18-23	3759-3767	clinical	_
18-24	3768-3776	outcomes	_
18-25	3777-3782	paper	_
18-26	3783-3784	.	_

Text=Nicotine dependence was characterized using the Fagerstrom Test for Nicotine Dependence (FTND).
19-1	3785-3793	Nicotine	_
19-2	3794-3804	dependence	_
19-3	3805-3808	was	_
19-4	3809-3822	characterized	_
19-5	3823-3828	using	_
19-6	3829-3832	the	_
19-7	3833-3843	Fagerstrom	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence
19-8	3844-3848	Test	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence
19-9	3849-3852	for	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence
19-10	3853-3861	Nicotine	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence
19-11	3862-3872	Dependence	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence
19-12	3873-3874	(	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence
19-13	3875-3879	FTND	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence
19-14	3880-3881	)	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence
19-15	3882-3883	.	_

Text=Nicotine withdrawal was assessed using the Wisconsin Smoking Withdrawal Scale (WSWS) and craving with the Questionnaire of Smoking Urges and were obtained 15–30 minutes before each MRI scan.
20-1	3884-3892	Nicotine	_
20-2	3893-3903	withdrawal	_
20-3	3904-3907	was	_
20-4	3908-3916	assessed	_
20-5	3917-3922	using	_
20-6	3923-3926	the	_
20-7	3927-3936	Wisconsin	http://maven.renci.org/NeuroBridge/neurobridge#WisconsinSmokingWithdrawalScale
20-8	3937-3944	Smoking	http://maven.renci.org/NeuroBridge/neurobridge#WisconsinSmokingWithdrawalScale
20-9	3945-3955	Withdrawal	http://maven.renci.org/NeuroBridge/neurobridge#WisconsinSmokingWithdrawalScale
20-10	3956-3961	Scale	http://maven.renci.org/NeuroBridge/neurobridge#WisconsinSmokingWithdrawalScale
20-11	3962-3963	(	http://maven.renci.org/NeuroBridge/neurobridge#WisconsinSmokingWithdrawalScale
20-12	3964-3968	WSWS	http://maven.renci.org/NeuroBridge/neurobridge#WisconsinSmokingWithdrawalScale
20-13	3969-3970	)	http://maven.renci.org/NeuroBridge/neurobridge#WisconsinSmokingWithdrawalScale
20-14	3971-3974	and	_
20-15	3975-3982	craving	_
20-16	3983-3987	with	_
20-17	3988-3991	the	_
20-18	3992-4005	Questionnaire	_
20-19	4006-4008	of	http://maven.renci.org/NeuroBridge/neurobridge#QuestionnaireonSmokingUrges
20-20	4009-4016	Smoking	http://maven.renci.org/NeuroBridge/neurobridge#QuestionnaireonSmokingUrges
20-21	4017-4022	Urges	http://maven.renci.org/NeuroBridge/neurobridge#QuestionnaireonSmokingUrges
20-22	4023-4026	and	_
20-23	4027-4031	were	_
20-24	4032-4040	obtained	_
20-25	4041-4046	15–30	_
20-26	4047-4054	minutes	_
20-27	4055-4061	before	_
20-28	4062-4066	each	_
20-29	4067-4070	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImagingInstrument
20-30	4071-4075	scan	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImagingInstrument
20-31	4076-4077	.	_

Text=A separate subscale of the WSWS [WSWS (food)] which included only the questions that were related to desire for food was calculated (see Supporting Information for details).
21-1	4078-4079	A	_
21-2	4080-4088	separate	_
21-3	4089-4097	subscale	_
21-4	4098-4100	of	_
21-5	4101-4104	the	_
21-6	4105-4109	WSWS	_
21-7	4110-4111	[	_
21-8	4112-4116	WSWS	_
21-9	4117-4118	(	_
21-10	4119-4123	food	_
21-11	4124-4125	)	_
21-12	4126-4127	]	_
21-13	4128-4133	which	_
21-14	4134-4142	included	_
21-15	4143-4147	only	_
21-16	4148-4151	the	_
21-17	4152-4161	questions	_
21-18	4162-4166	that	_
21-19	4167-4171	were	_
21-20	4172-4179	related	_
21-21	4180-4182	to	_
21-22	4183-4189	desire	_
21-23	4190-4193	for	_
21-24	4194-4198	food	_
21-25	4199-4202	was	_
21-26	4203-4213	calculated	_
21-27	4214-4215	(	_
21-28	4216-4219	see	_
21-29	4220-4230	Supporting	_
21-30	4231-4242	Information	_
21-31	4243-4246	for	_
21-32	4247-4254	details	_
21-33	4255-4256	)	_
21-34	4257-4258	.	_

Text=Number of hours since the last cigarette smoked was also obtained from the participant at the time of each MRI scan; participants were asked to be abstinent for 2 hours prior to the scan visit and there were only 8 participants who did not report being abstinent 2 hours prior to the scan.
22-1	4259-4265	Number	_
22-2	4266-4268	of	_
22-3	4269-4274	hours	_
22-4	4275-4280	since	_
22-5	4281-4284	the	_
22-6	4285-4289	last	_
22-7	4290-4299	cigarette	_
22-8	4300-4306	smoked	_
22-9	4307-4310	was	_
22-10	4311-4315	also	_
22-11	4316-4324	obtained	_
22-12	4325-4329	from	_
22-13	4330-4333	the	_
22-14	4334-4345	participant	_
22-15	4346-4348	at	_
22-16	4349-4352	the	_
22-17	4353-4357	time	_
22-18	4358-4360	of	_
22-19	4361-4365	each	_
22-20	4366-4369	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImagingInstrument
22-21	4370-4374	scan	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImagingInstrument
22-22	4375-4376	;	_
22-23	4377-4389	participants	_
22-24	4390-4394	were	_
22-25	4395-4400	asked	_
22-26	4401-4403	to	_
22-27	4404-4406	be	_
22-28	4407-4416	abstinent	_
22-29	4417-4420	for	_
22-30	4421-4422	2	_
22-31	4423-4428	hours	_
22-32	4429-4434	prior	_
22-33	4435-4437	to	_
22-34	4438-4441	the	_
22-35	4442-4446	scan	_
22-36	4447-4452	visit	_
22-37	4453-4456	and	_
22-38	4457-4462	there	_
22-39	4463-4467	were	_
22-40	4468-4472	only	_
22-41	4473-4474	8	_
22-42	4475-4487	participants	_
22-43	4488-4491	who	_
22-44	4492-4495	did	_
22-45	4496-4499	not	_
22-46	4500-4506	report	_
22-47	4507-4512	being	_
22-48	4513-4522	abstinent	_
22-49	4523-4524	2	_
22-50	4525-4530	hours	_
22-51	4531-4536	prior	_
22-52	4537-4539	to	_
22-53	4540-4543	the	_
22-54	4544-4548	scan	_
22-55	4549-4550	.	_

Text=Additional measures included the Beck Anxiety Inventory (BAI), the Beck Depression Inventory (BDI), the Barratt Impulsiveness Questionnaire (BIQ), and the Alcohol Use Disorders Identification Test (AUDIT) (references for self-report measures listed in Supporting Information).
23-1	4551-4561	Additional	_
23-2	4562-4570	measures	_
23-3	4571-4579	included	_
23-4	4580-4583	the	_
23-5	4584-4588	Beck	http://maven.renci.org/NeuroBridge/neurobridge#TraitAnxietyInventory
23-6	4589-4596	Anxiety	http://maven.renci.org/NeuroBridge/neurobridge#TraitAnxietyInventory
23-7	4597-4606	Inventory	http://maven.renci.org/NeuroBridge/neurobridge#TraitAnxietyInventory
23-8	4607-4608	(	http://maven.renci.org/NeuroBridge/neurobridge#TraitAnxietyInventory
23-9	4609-4612	BAI	http://maven.renci.org/NeuroBridge/neurobridge#TraitAnxietyInventory
23-10	4613-4614	)	http://maven.renci.org/NeuroBridge/neurobridge#TraitAnxietyInventory
23-11	4615-4616	,	_
23-12	4617-4620	the	_
23-13	4621-4625	Beck	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory
23-14	4626-4636	Depression	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory
23-15	4637-4646	Inventory	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory
23-16	4647-4648	(	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory
23-17	4649-4652	BDI	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory
23-18	4653-4654	)	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory
23-19	4655-4656	,	_
23-20	4657-4660	the	_
23-21	4661-4668	Barratt	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire
23-22	4669-4682	Impulsiveness	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire
23-23	4683-4696	Questionnaire	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire
23-24	4697-4698	(	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire
23-25	4699-4702	BIQ	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire
23-26	4703-4704	)	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire
23-27	4705-4706	,	_
23-28	4707-4710	and	_
23-29	4711-4714	the	_
23-30	4715-4722	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
23-31	4723-4726	Use	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
23-32	4727-4736	Disorders	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
23-33	4737-4751	Identification	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
23-34	4752-4756	Test	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
23-35	4757-4758	(	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
23-36	4759-4764	AUDIT	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
23-37	4765-4766	)	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
23-38	4767-4768	(	_
23-39	4769-4779	references	_
23-40	4780-4783	for	_
23-41	4784-4795	self-report	_
23-42	4796-4804	measures	_
23-43	4805-4811	listed	_
23-44	4812-4814	in	_
23-45	4815-4825	Supporting	_
23-46	4826-4837	Information	_
23-47	4838-4839	)	_
23-48	4840-4841	.	_

Text=All participants were also asked at the screen visit about the number of prior serious quit attempts they had made in their lives during which they remained abstinent from cigarettes for 12 hours or more.
24-1	4842-4845	All	_
24-2	4846-4858	participants	_
24-3	4859-4863	were	_
24-4	4864-4868	also	_
24-5	4869-4874	asked	_
24-6	4875-4877	at	_
24-7	4878-4881	the	_
24-8	4882-4888	screen	_
24-9	4889-4894	visit	_
24-10	4895-4900	about	_
24-11	4901-4904	the	_
24-12	4905-4911	number	_
24-13	4912-4914	of	_
24-14	4915-4920	prior	_
24-15	4921-4928	serious	_
24-16	4929-4933	quit	_
24-17	4934-4942	attempts	_
24-18	4943-4947	they	_
24-19	4948-4951	had	_
24-20	4952-4956	made	_
24-21	4957-4959	in	_
24-22	4960-4965	their	_
24-23	4966-4971	lives	_
24-24	4972-4978	during	_
24-25	4979-4984	which	_
24-26	4985-4989	they	_
24-27	4990-4998	remained	_
24-28	4999-5008	abstinent	_
24-29	5009-5013	from	_
24-30	5014-5024	cigarettes	_
24-31	5025-5028	for	_
24-32	5029-5031	12	_
24-33	5032-5037	hours	_
24-34	5038-5040	or	_
24-35	5041-5045	more	_
24-36	5046-5047	.	_

Text=Carbon monoxide (CO) levels were obtained at all visits which were used to validate secondary abstinence-based outcome variables (Tables 6,7, S1–3).
25-1	5048-5054	Carbon	_
25-2	5055-5063	monoxide	_
25-3	5064-5065	(	_
25-4	5066-5068	CO	_
25-5	5069-5070	)	_
25-6	5071-5077	levels	_
25-7	5078-5082	were	_
25-8	5083-5091	obtained	_
25-9	5092-5094	at	_
25-10	5095-5098	all	_
25-11	5099-5105	visits	_
25-12	5106-5111	which	_
25-13	5112-5116	were	_
25-14	5117-5121	used	_
25-15	5122-5124	to	_
25-16	5125-5133	validate	_
25-17	5134-5143	secondary	_
25-18	5144-5160	abstinence-based	_
25-19	5161-5168	outcome	_
25-20	5169-5178	variables	_
25-21	5179-5180	(	_
25-22	5181-5187	Tables	_
25-23	5188-5191	6,7	_
25-24	5192-5193	,	_
25-25	5194-5198	S1–3	_
25-26	5199-5200	)	_
25-27	5201-5202	.	_

Text=The time-line follow-back procedure (TLFB) (reference in Supporting Information) was used to record tobacco product, alcohol, and drug use in the 60 days prior to the screen and during the interim period between each follow-up assessment.
26-1	5203-5206	The	_
26-2	5207-5216	time-line	_
26-3	5217-5228	follow-back	_
26-4	5229-5238	procedure	_
26-5	5239-5240	(	_
26-6	5241-5245	TLFB	_
26-7	5246-5247	)	_
26-8	5248-5249	(	_
26-9	5250-5259	reference	_
26-10	5260-5262	in	_
26-11	5263-5273	Supporting	_
26-12	5274-5285	Information	_
26-13	5286-5287	)	_
26-14	5288-5291	was	_
26-15	5292-5296	used	_
26-16	5297-5299	to	_
26-17	5300-5306	record	_
26-18	5307-5314	tobacco	_
26-19	5315-5322	product	_
26-20	5323-5324	,	_
26-21	5325-5332	alcohol	_
26-22	5333-5334	,	_
26-23	5335-5338	and	_
26-24	5339-5343	drug	_
26-25	5344-5347	use	_
26-26	5348-5350	in	_
26-27	5351-5354	the	_
26-28	5355-5357	60	_
26-29	5358-5362	days	_
26-30	5363-5368	prior	_
26-31	5369-5371	to	_
26-32	5372-5375	the	_
26-33	5376-5382	screen	_
26-34	5383-5386	and	_
26-35	5387-5393	during	_
26-36	5394-5397	the	_
26-37	5398-5405	interim	_
26-38	5406-5412	period	_
26-39	5413-5420	between	_
26-40	5421-5425	each	_
26-41	5426-5435	follow-up	_
26-42	5436-5446	assessment	_
26-43	5447-5448	.	_

Text=The baseline smoking rate was calculated as the total number of cigarettes smoked (NumCig) during the 60 days before the screen visit.
27-1	5449-5452	The	_
27-2	5453-5461	baseline	_
27-3	5462-5469	smoking	_
27-4	5470-5474	rate	_
27-5	5475-5478	was	_
27-6	5479-5489	calculated	_
27-7	5490-5492	as	_
27-8	5493-5496	the	_
27-9	5497-5502	total	_
27-10	5503-5509	number	_
27-11	5510-5512	of	_
27-12	5513-5523	cigarettes	_
27-13	5524-5530	smoked	_
27-14	5531-5532	(	_
27-15	5533-5539	NumCig	_
27-16	5540-5541	)	_
27-17	5542-5548	during	_
27-18	5549-5552	the	_
27-19	5553-5555	60	_
27-20	5556-5560	days	_
27-21	5561-5567	before	_
27-22	5568-5571	the	_
27-23	5572-5578	screen	_
27-24	5579-5584	visit	_
27-25	5585-5586	.	_

Text=Low rates of complete abstinence in the placebo group (n=4 at 6 weeks for 7 day point prevalence) rendered logistic regression problematic as a method of analysis to examine the interaction term [component beta × treatment group (RxGrp)], given small sample bias.
28-1	5587-5590	Low	_
28-2	5591-5596	rates	_
28-3	5597-5599	of	_
28-4	5600-5608	complete	_
28-5	5609-5619	abstinence	_
28-6	5620-5622	in	_
28-7	5623-5626	the	_
28-8	5627-5634	placebo	_
28-9	5635-5640	group	_
28-10	5641-5642	(	_
28-11	5643-5646	n=4	_
28-12	5647-5649	at	_
28-13	5650-5651	6	_
28-14	5652-5657	weeks	_
28-15	5658-5661	for	_
28-16	5662-5663	7	_
28-17	5664-5667	day	_
28-18	5668-5673	point	_
28-19	5674-5684	prevalence	_
28-20	5685-5686	)	_
28-21	5687-5695	rendered	_
28-22	5696-5704	logistic	_
28-23	5705-5715	regression	_
28-24	5716-5727	problematic	_
28-25	5728-5730	as	_
28-26	5731-5732	a	_
28-27	5733-5739	method	_
28-28	5740-5742	of	_
28-29	5743-5751	analysis	_
28-30	5752-5754	to	_
28-31	5755-5762	examine	_
28-32	5763-5766	the	_
28-33	5767-5778	interaction	_
28-34	5779-5783	term	_
28-35	5784-5785	[	_
28-36	5786-5795	component	_
28-37	5796-5800	beta	_
28-38	5801-5802	×	_
28-39	5803-5812	treatment	_
28-40	5813-5818	group	_
28-41	5819-5820	(	_
28-42	5821-5826	RxGrp	_
28-43	5827-5828	)	_
28-44	5829-5830	]	_
28-45	5831-5832	,	_
28-46	5833-5838	given	_
28-47	5839-5844	small	_
28-48	5845-5851	sample	_
28-49	5852-5856	bias	_
28-50	5857-5858	.	_

Text=We therefore utilized continuous outcome variables as our primary outcome: NumCig during the previous 28 days for the 6 week smoking outcome and NumCig during the previous 30 days for the 12 week smoking outcome.
29-1	5859-5861	We	_
29-2	5862-5871	therefore	_
29-3	5872-5880	utilized	_
29-4	5881-5891	continuous	_
29-5	5892-5899	outcome	_
29-6	5900-5909	variables	_
29-7	5910-5912	as	_
29-8	5913-5916	our	_
29-9	5917-5924	primary	_
29-10	5925-5932	outcome	_
29-11	5933-5934	:	_
29-12	5935-5941	NumCig	_
29-13	5942-5948	during	_
29-14	5949-5952	the	_
29-15	5953-5961	previous	_
29-16	5962-5964	28	_
29-17	5965-5969	days	_
29-18	5970-5973	for	_
29-19	5974-5977	the	_
29-20	5978-5979	6	_
29-21	5980-5984	week	_
29-22	5985-5992	smoking	_
29-23	5993-6000	outcome	_
29-24	6001-6004	and	_
29-25	6005-6011	NumCig	_
29-26	6012-6018	during	_
29-27	6019-6022	the	_
29-28	6023-6031	previous	_
29-29	6032-6034	30	_
29-30	6035-6039	days	_
29-31	6040-6043	for	_
29-32	6044-6047	the	_
29-33	6048-6050	12	_
29-34	6051-6055	week	_
29-35	6056-6063	smoking	_
29-36	6064-6071	outcome	_
29-37	6072-6073	.	_

Text=Although abstinence is more commonly used as a measure of success in smoking cessation trials, smoking reduction is still a meaningful outcome that predicts later cessation.
30-1	6074-6082	Although	_
30-2	6083-6093	abstinence	_
30-3	6094-6096	is	_
30-4	6097-6101	more	_
30-5	6102-6110	commonly	_
30-6	6111-6115	used	_
30-7	6116-6118	as	_
30-8	6119-6120	a	_
30-9	6121-6128	measure	_
30-10	6129-6131	of	_
30-11	6132-6139	success	_
30-12	6140-6142	in	_
30-13	6143-6150	smoking	_
30-14	6151-6160	cessation	_
30-15	6161-6167	trials	_
30-16	6168-6169	,	_
30-17	6170-6177	smoking	_
30-18	6178-6187	reduction	_
30-19	6188-6190	is	_
30-20	6191-6196	still	_
30-21	6197-6198	a	_
30-22	6199-6209	meaningful	_
30-23	6210-6217	outcome	_
30-24	6218-6222	that	_
30-25	6223-6231	predicts	_
30-26	6232-6237	later	_
30-27	6238-6247	cessation	_
30-28	6248-6249	.	_

Text=For dropouts, missing outcomes data were imputed to an adjusted screen visit value [eg.
31-1	6250-6253	For	_
31-2	6254-6262	dropouts	_
31-3	6263-6264	,	_
31-4	6265-6272	missing	_
31-5	6273-6281	outcomes	_
31-6	6282-6286	data	_
31-7	6287-6291	were	_
31-8	6292-6299	imputed	_
31-9	6300-6302	to	_
31-10	6303-6305	an	_
31-11	6306-6314	adjusted	_
31-12	6315-6321	screen	_
31-13	6322-6327	visit	_
31-14	6328-6333	value	_
31-15	6334-6335	[	_
31-16	6336-6338	eg	_
31-17	6339-6340	.	_

Text=(NumCig at screen visit) * 28/60 = NumCig at 6 weeks] (n=27/143 for week 6 and n=44/143 for week 12) for our primary analysis.
32-1	6341-6342	(	_
32-2	6343-6349	NumCig	_
32-3	6350-6352	at	_
32-4	6353-6359	screen	_
32-5	6360-6365	visit	_
32-6	6366-6367	)	_
32-7	6368-6369	*	_
32-8	6370-6375	28/60	_
32-9	6376-6377	=	_
32-10	6378-6384	NumCig	_
32-11	6385-6387	at	_
32-12	6388-6389	6	_
32-13	6390-6395	weeks	_
32-14	6396-6397	]	_
32-15	6398-6399	(	_
32-16	6400-6408	n=27/143	_
32-17	6409-6412	for	_
32-18	6413-6417	week	_
32-19	6418-6419	6	_
32-20	6420-6423	and	_
32-21	6424-6432	n=44/143	_
32-22	6433-6436	for	_
32-23	6437-6441	week	_
32-24	6442-6444	12	_
32-25	6445-6446	)	_
32-26	6447-6450	for	_
32-27	6451-6454	our	_
32-28	6455-6462	primary	_
32-29	6463-6471	analysis	_
32-30	6472-6473	.	_

Text=Imputing to baseline (assuming missing subjects revert to baseline smoking levels) is a common approach for smoking cessation clinical trials even when rates of dropout approach ours.
33-1	6474-6482	Imputing	_
33-2	6483-6485	to	_
33-3	6486-6494	baseline	_
33-4	6495-6496	(	_
33-5	6497-6505	assuming	_
33-6	6506-6513	missing	_
33-7	6514-6522	subjects	_
33-8	6523-6529	revert	_
33-9	6530-6532	to	_
33-10	6533-6541	baseline	_
33-11	6542-6549	smoking	_
33-12	6550-6556	levels	_
33-13	6557-6558	)	_
33-14	6559-6561	is	_
33-15	6562-6563	a	_
33-16	6564-6570	common	_
33-17	6571-6579	approach	_
33-18	6580-6583	for	_
33-19	6584-6591	smoking	_
33-20	6592-6601	cessation	_
33-21	6602-6610	clinical	_
33-22	6611-6617	trials	_
33-23	6618-6622	even	_
33-24	6623-6627	when	_
33-25	6628-6633	rates	_
33-26	6634-6636	of	_
33-27	6637-6644	dropout	_
33-28	6645-6653	approach	_
33-29	6654-6658	ours	_
33-30	6659-6660	.	_

Text=We also present results for an analysis performed on individuals with complete data.
34-1	6661-6663	We	_
34-2	6664-6668	also	_
34-3	6669-6676	present	_
34-4	6677-6684	results	_
34-5	6685-6688	for	_
34-6	6689-6691	an	_
34-7	6692-6700	analysis	_
34-8	6701-6710	performed	_
34-9	6711-6713	on	_
34-10	6714-6725	individuals	_
34-11	6726-6730	with	_
34-12	6731-6739	complete	_
34-13	6740-6744	data	_
34-14	6745-6746	.	_

Text=Cue-Exposure Task The cue-exposure task is identical to the task for which results in a different sample of non treatment-seeking smokers is published (details in Supporting Information).
35-1	6747-6759	Cue-Exposure	_
35-2	6760-6764	Task	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
35-3	6765-6768	The	_
35-4	6769-6781	cue-exposure	_
35-5	6782-6786	task	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
35-6	6787-6789	is	_
35-7	6790-6799	identical	_
35-8	6800-6802	to	_
35-9	6803-6806	the	_
35-10	6807-6811	task	_
35-11	6812-6815	for	_
35-12	6816-6821	which	_
35-13	6822-6829	results	_
35-14	6830-6832	in	_
35-15	6833-6834	a	_
35-16	6835-6844	different	_
35-17	6845-6851	sample	_
35-18	6852-6854	of	_
35-19	6855-6858	non	_
35-20	6859-6876	treatment-seeking	_
35-21	6877-6884	smokers	_
35-22	6885-6887	is	_
35-23	6888-6897	published	_
35-24	6898-6899	(	_
35-25	6900-6907	details	_
35-26	6908-6910	in	_
35-27	6911-6921	Supporting	_
35-28	6922-6933	Information	_
35-29	6934-6935	)	_
35-30	6936-6937	.	_

Text=In brief, the task consisted of two 6-min runs with pseudorandom presentations of seven different smoking- related videos and seven different food-related videos per run, ranging in length from 7 to 14 seconds, and depicting images of preparation of the stimulus for ingestion and the act of ingestion itself.
36-1	6938-6940	In	_
36-2	6941-6946	brief	_
36-3	6947-6948	,	_
36-4	6949-6952	the	_
36-5	6953-6957	task	_
36-6	6958-6967	consisted	_
36-7	6968-6970	of	_
36-8	6971-6974	two	_
36-9	6975-6980	6-min	_
36-10	6981-6985	runs	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
36-11	6986-6990	with	_
36-12	6991-7003	pseudorandom	_
36-13	7004-7017	presentations	http://maven.renci.org/NeuroBridge/neurobridge#QualityOfLifeQuestionnaire
36-14	7018-7020	of	http://maven.renci.org/NeuroBridge/neurobridge#QualityOfLifeQuestionnaire
36-15	7021-7026	seven	_
36-16	7027-7036	different	_
36-17	7037-7045	smoking-	_
36-18	7046-7053	related	_
36-19	7054-7060	videos	http://maven.renci.org/NeuroBridge/neurobridge#Triglycerides
36-20	7061-7064	and	_
36-21	7065-7070	seven	_
36-22	7071-7080	different	_
36-23	7081-7093	food-related	_
36-24	7094-7100	videos	http://maven.renci.org/NeuroBridge/neurobridge#Triglycerides
36-25	7101-7104	per	_
36-26	7105-7108	run	_
36-27	7109-7110	,	_
36-28	7111-7118	ranging	_
36-29	7119-7121	in	_
36-30	7122-7128	length	_
36-31	7129-7133	from	_
36-32	7134-7135	7	_
36-33	7136-7138	to	_
36-34	7139-7141	14	_
36-35	7142-7149	seconds	_
36-36	7150-7151	,	_
36-37	7152-7155	and	_
36-38	7156-7165	depicting	_
36-39	7166-7172	images	_
36-40	7173-7175	of	_
36-41	7176-7187	preparation	_
36-42	7188-7190	of	_
36-43	7191-7194	the	_
36-44	7195-7203	stimulus	_
36-45	7204-7207	for	_
36-46	7208-7217	ingestion	_
36-47	7218-7221	and	_
36-48	7222-7225	the	_
36-49	7226-7229	act	_
36-50	7230-7232	of	_
36-51	7233-7242	ingestion	_
36-52	7243-7249	itself	_
36-53	7250-7251	.	_

Text=MRI Acquisition and Preprocessing All scans were acquired on a Siemens 3T Trio scanner located at the Mind Research Network in Albuquerque NM using procedures previously described.
37-1	7252-7255	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
37-2	7256-7267	Acquisition	_
37-3	7268-7271	and	_
37-4	7272-7285	Preprocessing	_
37-5	7286-7289	All	_
37-6	7290-7295	scans	_
37-7	7296-7300	were	_
37-8	7301-7309	acquired	_
37-9	7310-7312	on	_
37-10	7313-7314	a	_
37-11	7315-7322	Siemens	_
37-12	7323-7325	3T	_
37-13	7326-7330	Trio	_
37-14	7331-7338	scanner	_
37-15	7339-7346	located	_
37-16	7347-7349	at	_
37-17	7350-7353	the	_
37-18	7354-7358	Mind	_
37-19	7359-7367	Research	_
37-20	7368-7375	Network	_
37-21	7376-7378	in	_
37-22	7379-7390	Albuquerque	_
37-23	7391-7393	NM	_
37-24	7394-7399	using	_
37-25	7400-7410	procedures	_
37-26	7411-7421	previously	_
37-27	7422-7431	described	_
37-28	7432-7433	.	_

Text=Data were preprocessed using SPM5 software (http: //fil.ion.ucl.ac.uk/spm/software/spm5) using standard methods (details in Supporting Information).
38-1	7434-7438	Data	_
38-2	7439-7443	were	_
38-3	7444-7456	preprocessed	_
38-4	7457-7462	using	_
38-5	7463-7467	SPM5	_
38-6	7468-7476	software	_
38-7	7477-7478	(	_
38-8	7479-7483	http	_
38-9	7484-7485	:	_
38-10	7486-7523	//fil.ion.ucl.ac.uk/spm/software/spm5	_
38-11	7524-7525	)	_
38-12	7526-7531	using	_
38-13	7532-7540	standard	_
38-14	7541-7548	methods	_
38-15	7549-7550	(	_
38-16	7551-7558	details	_
38-17	7559-7561	in	_
38-18	7562-7572	Supporting	_
38-19	7573-7584	Information	_
38-20	7585-7586	)	_
38-21	7587-7588	.	_

Text=ICA Methods Infomax group spatial ICA was conducted to decompose the data into components using GIFT software (http: //mialab.mrn.org/software/gift).
39-1	7589-7592	ICA	_
39-2	7593-7600	Methods	http://maven.renci.org/NeuroBridge/neurobridge#DataCollectionMethod
39-3	7601-7608	Infomax	_
39-4	7609-7614	group	_
39-5	7615-7622	spatial	_
39-6	7623-7626	ICA	_
39-7	7627-7630	was	_
39-8	7631-7640	conducted	_
39-9	7641-7643	to	_
39-10	7644-7653	decompose	_
39-11	7654-7657	the	_
39-12	7658-7662	data	_
39-13	7663-7667	into	_
39-14	7668-7678	components	_
39-15	7679-7684	using	_
39-16	7685-7689	GIFT	_
39-17	7690-7698	software	_
39-18	7699-7700	(	_
39-19	7701-7705	http	_
39-20	7706-7707	:	_
39-21	7708-7738	//mialab.mrn.org/software/gift	_
39-22	7739-7740	)	_
39-23	7741-7742	.	_

Text=35 components for the previous data reduction step, and 30 components for the final data reduction step were chosen (typical for low order models).
40-1	7743-7745	35	_
40-2	7746-7756	components	_
40-3	7757-7760	for	_
40-4	7761-7764	the	_
40-5	7765-7773	previous	_
40-6	7774-7778	data	_
40-7	7779-7788	reduction	_
40-8	7789-7793	step	_
40-9	7794-7795	,	_
40-10	7796-7799	and	_
40-11	7800-7802	30	_
40-12	7803-7813	components	_
40-13	7814-7817	for	_
40-14	7818-7821	the	_
40-15	7822-7827	final	_
40-16	7828-7832	data	_
40-17	7833-7842	reduction	_
40-18	7843-7847	step	_
40-19	7848-7852	were	_
40-20	7853-7859	chosen	_
40-21	7860-7861	(	_
40-22	7862-7869	typical	_
40-23	7870-7873	for	_
40-24	7874-7877	low	_
40-25	7878-7883	order	_
40-26	7884-7890	models	_
40-27	7891-7892	)	_
40-28	7893-7894	.	_

Text=To estimate subject-specific spatial maps and time-courses, the GICA back-reconstruction method was used.
41-1	7895-7897	To	_
41-2	7898-7906	estimate	_
41-3	7907-7923	subject-specific	_
41-4	7924-7931	spatial	_
41-5	7932-7936	maps	_
41-6	7937-7940	and	_
41-7	7941-7953	time-courses	_
41-8	7954-7955	,	_
41-9	7956-7959	the	_
41-10	7960-7964	GICA	_
41-11	7965-7984	back-reconstruction	_
41-12	7985-7991	method	_
41-13	7992-7995	was	_
41-14	7996-8000	used	_
41-15	8001-8002	.	_

Text=ICA was repeated 10 times using ICASSO (http: //research.ics.aalto.fi/ica/icasso/) and the “ best run ” was selected to mitigate variation due to the stochastic estimation process.
42-1	8003-8006	ICA	_
42-2	8007-8010	was	_
42-3	8011-8019	repeated	_
42-4	8020-8022	10	_
42-5	8023-8028	times	_
42-6	8029-8034	using	_
42-7	8035-8041	ICASSO	_
42-8	8042-8043	(	_
42-9	8044-8048	http	_
42-10	8049-8050	:	_
42-11	8051-8086	//research.ics.aalto.fi/ica/icasso/	_
42-12	8087-8088	)	_
42-13	8089-8092	and	_
42-14	8093-8096	the	_
42-15	8097-8098	“	_
42-16	8099-8103	best	_
42-17	8104-8107	run	_
42-18	8108-8109	”	_
42-19	8110-8113	was	_
42-20	8114-8122	selected	_
42-21	8123-8125	to	_
42-22	8126-8134	mitigate	_
42-23	8135-8144	variation	_
42-24	8145-8148	due	_
42-25	8149-8151	to	_
42-26	8152-8155	the	_
42-27	8156-8166	stochastic	_
42-28	8167-8177	estimation	_
42-29	8178-8185	process	_
42-30	8186-8187	.	_

Text=The resulting component runs were also clustered to estimate the reliability of the decomposition.
43-1	8188-8191	The	_
43-2	8192-8201	resulting	_
43-3	8202-8211	component	_
43-4	8212-8216	runs	_
43-5	8217-8221	were	_
43-6	8222-8226	also	_
43-7	8227-8236	clustered	_
43-8	8237-8239	to	_
43-9	8240-8248	estimate	_
43-10	8249-8252	the	_
43-11	8253-8264	reliability	_
43-12	8265-8267	of	_
43-13	8268-8271	the	_
43-14	8272-8285	decomposition	_
43-15	8286-8287	.	_

Text=Robustness and reliability of components were well-validated by the ICASSO results showing compact and independent/non-overlapping clusters.
44-1	8288-8298	Robustness	_
44-2	8299-8302	and	_
44-3	8303-8314	reliability	_
44-4	8315-8317	of	_
44-5	8318-8328	components	_
44-6	8329-8333	were	_
44-7	8334-8348	well-validated	_
44-8	8349-8351	by	_
44-9	8352-8355	the	_
44-10	8356-8362	ICASSO	_
44-11	8363-8370	results	_
44-12	8371-8378	showing	_
44-13	8379-8386	compact	_
44-14	8387-8390	and	_
44-15	8391-8418	independent/non-overlapping	_
44-16	8419-8427	clusters	_
44-17	8428-8429	.	_

Text=Following ICA, time series were filtered using a low-pass filter of> 0.15 Hz, and detrending to remove low frequency noise (high-pass filter).
45-1	8430-8439	Following	_
45-2	8440-8443	ICA	_
45-3	8444-8445	,	_
45-4	8446-8450	time	_
45-5	8451-8457	series	_
45-6	8458-8462	were	_
45-7	8463-8471	filtered	_
45-8	8472-8477	using	_
45-9	8478-8479	a	_
45-10	8480-8488	low-pass	_
45-11	8489-8495	filter	_
45-12	8496-8498	of	_
45-13	8499-8500	>	_
45-14	8501-8505	0.15	_
45-15	8506-8508	Hz	_
45-16	8509-8510	,	_
45-17	8511-8514	and	_
45-18	8515-8525	detrending	_
45-19	8526-8528	to	_
45-20	8529-8535	remove	_
45-21	8536-8539	low	_
45-22	8540-8549	frequency	_
45-23	8550-8555	noise	_
45-24	8556-8557	(	_
45-25	8558-8567	high-pass	_
45-26	8568-8574	filter	_
45-27	8575-8576	)	_
45-28	8577-8578	.	_

Text=To correct for head motion, time series were then despiked, and motion was regressed out on a per-subject basis using the six motion parameters.
46-1	8579-8581	To	_
46-2	8582-8589	correct	_
46-3	8590-8593	for	_
46-4	8594-8598	head	_
46-5	8599-8605	motion	_
46-6	8606-8607	,	_
46-7	8608-8612	time	_
46-8	8613-8619	series	_
46-9	8620-8624	were	_
46-10	8625-8629	then	_
46-11	8630-8638	despiked	_
46-12	8639-8640	,	_
46-13	8641-8644	and	_
46-14	8645-8651	motion	_
46-15	8652-8655	was	_
46-16	8656-8665	regressed	_
46-17	8666-8669	out	_
46-18	8670-8672	on	_
46-19	8673-8674	a	_
46-20	8675-8686	per-subject	_
46-21	8687-8692	basis	_
46-22	8693-8698	using	_
46-23	8699-8702	the	_
46-24	8703-8706	six	_
46-25	8707-8713	motion	_
46-26	8714-8724	parameters	_
46-27	8725-8726	.	_

Text=In addition, mean root mean squared translational (rmsTrans) and rotational (rmsRot) framewise displacement (FD) were calculated for each subject.
47-1	8727-8729	In	_
47-2	8730-8738	addition	_
47-3	8739-8740	,	_
47-4	8741-8745	mean	_
47-5	8746-8750	root	_
47-6	8751-8755	mean	_
47-7	8756-8763	squared	_
47-8	8764-8777	translational	_
47-9	8778-8779	(	_
47-10	8780-8788	rmsTrans	_
47-11	8789-8790	)	_
47-12	8791-8794	and	_
47-13	8795-8805	rotational	_
47-14	8806-8807	(	_
47-15	8808-8814	rmsRot	_
47-16	8815-8816	)	_
47-17	8817-8826	framewise	_
47-18	8827-8839	displacement	_
47-19	8840-8841	(	_
47-20	8842-8844	FD	_
47-21	8845-8846	)	_
47-22	8847-8851	were	_
47-23	8852-8862	calculated	_
47-24	8863-8866	for	_
47-25	8867-8871	each	_
47-26	8872-8879	subject	_
47-27	8880-8881	.	_

Text=Component Selection Spatial maps were reconstructed and converted to Z values for each of the subjects.
48-1	8882-8891	Component	_
48-2	8892-8901	Selection	_
48-3	8902-8909	Spatial	_
48-4	8910-8914	maps	_
48-5	8915-8919	were	_
48-6	8920-8933	reconstructed	_
48-7	8934-8937	and	_
48-8	8938-8947	converted	_
48-9	8948-8950	to	_
48-10	8951-8952	Z	_
48-11	8953-8959	values	_
48-12	8960-8963	for	_
48-13	8964-8968	each	_
48-14	8969-8971	of	_
48-15	8972-8975	the	_
48-16	8976-8984	subjects	_
48-17	8985-8986	.	_

Text=A standardized DMN mask [rDMN_ICA_REST * .nii; http: //mialab.mrn.org/data] was used to select the DMN component from the 30 estimated components using the spatial sort function in GIFT; we selected the component which was most strongly associated with our apriori template R2 = 0.42) (Figure 1a).
49-1	8987-8988	A	_
49-2	8989-9001	standardized	_
49-3	9002-9005	DMN	_
49-4	9006-9010	mask	_
49-5	9011-9012	[	_
49-6	9013-9026	rDMN_ICA_REST	_
49-7	9027-9028	*	_
49-8	9029-9033	.nii	_
49-9	9034-9035	;	_
49-10	9036-9040	http	_
49-11	9041-9042	:	_
49-12	9043-9064	//mialab.mrn.org/data	_
49-13	9065-9066	]	_
49-14	9067-9070	was	_
49-15	9071-9075	used	_
49-16	9076-9078	to	_
49-17	9079-9085	select	_
49-18	9086-9089	the	_
49-19	9090-9093	DMN	_
49-20	9094-9103	component	_
49-21	9104-9108	from	_
49-22	9109-9112	the	_
49-23	9113-9115	30	_
49-24	9116-9125	estimated	_
49-25	9126-9136	components	_
49-26	9137-9142	using	_
49-27	9143-9146	the	_
49-28	9147-9154	spatial	_
49-29	9155-9159	sort	_
49-30	9160-9168	function	_
49-31	9169-9171	in	_
49-32	9172-9176	GIFT	_
49-33	9177-9178	;	_
49-34	9179-9181	we	_
49-35	9182-9190	selected	_
49-36	9191-9194	the	_
49-37	9195-9204	component	_
49-38	9205-9210	which	_
49-39	9211-9214	was	_
49-40	9215-9219	most	_
49-41	9220-9228	strongly	_
49-42	9229-9239	associated	_
49-43	9240-9244	with	_
49-44	9245-9248	our	_
49-45	9249-9256	apriori	_
49-46	9257-9265	template	_
49-47	9266-9268	R2	_
49-48	9269-9270	=	_
49-49	9271-9275	0.42	_
49-50	9276-9277	)	_
49-51	9278-9279	(	_
49-52	9280-9286	Figure	_
49-53	9287-9289	1a	_
49-54	9290-9291	)	_
49-55	9292-9293	.	_

Text=This method was chosen so that our analyses could be systematically replicated in other samples.
50-1	9294-9298	This	_
50-2	9299-9305	method	_
50-3	9306-9309	was	_
50-4	9310-9316	chosen	_
50-5	9317-9319	so	_
50-6	9320-9324	that	_
50-7	9325-9328	our	_
50-8	9329-9337	analyses	_
50-9	9338-9343	could	_
50-10	9344-9346	be	_
50-11	9347-9361	systematically	_
50-12	9362-9372	replicated	_
50-13	9373-9375	in	_
50-14	9376-9381	other	_
50-15	9382-9389	samples	_
50-16	9390-9391	.	_

Text=Compared to rest, previous works have shown that tasks may also modulate some of the spatial maps, but the change is not large, so the use of a rest DMN template is reasonable.
51-1	9392-9400	Compared	_
51-2	9401-9403	to	_
51-3	9404-9408	rest	_
51-4	9409-9410	,	_
51-5	9411-9419	previous	_
51-6	9420-9425	works	_
51-7	9426-9430	have	_
51-8	9431-9436	shown	_
51-9	9437-9441	that	_
51-10	9442-9447	tasks	_
51-11	9448-9451	may	_
51-12	9452-9456	also	_
51-13	9457-9465	modulate	_
51-14	9466-9470	some	_
51-15	9471-9473	of	_
51-16	9474-9477	the	_
51-17	9478-9485	spatial	_
51-18	9486-9490	maps	_
51-19	9491-9492	,	_
51-20	9493-9496	but	_
51-21	9497-9500	the	_
51-22	9501-9507	change	_
51-23	9508-9510	is	_
51-24	9511-9514	not	_
51-25	9515-9520	large	_
51-26	9521-9522	,	_
51-27	9523-9525	so	_
51-28	9526-9529	the	_
51-29	9530-9533	use	_
51-30	9534-9536	of	_
51-31	9537-9538	a	_
51-32	9539-9543	rest	_
51-33	9544-9547	DMN	_
51-34	9548-9556	template	_
51-35	9557-9559	is	_
51-36	9560-9570	reasonable	_
51-37	9571-9572	.	_

Text=The ECN [right (R) and left (L)] and SN were identified visually by anatomical overlap with previous studies of these networks in smokers.
52-1	9573-9576	The	_
52-2	9577-9580	ECN	_
52-3	9581-9582	[	_
52-4	9583-9588	right	_
52-5	9589-9590	(	_
52-6	9591-9592	R	_
52-7	9593-9594	)	_
52-8	9595-9598	and	_
52-9	9599-9603	left	_
52-10	9604-9605	(	_
52-11	9606-9607	L	_
52-12	9608-9609	)	_
52-13	9610-9611	]	_
52-14	9612-9615	and	_
52-15	9616-9618	SN	_
52-16	9619-9623	were	_
52-17	9624-9634	identified	_
52-18	9635-9643	visually	_
52-19	9644-9646	by	_
52-20	9647-9657	anatomical	_
52-21	9658-9665	overlap	_
52-22	9666-9670	with	_
52-23	9671-9679	previous	_
52-24	9680-9687	studies	_
52-25	9688-9690	of	_
52-26	9691-9696	these	_
52-27	9697-9705	networks	_
52-28	9706-9708	in	_
52-29	9709-9716	smokers	_
52-30	9717-9718	.	_

Text=Temporal Sort and Development of the Component Predictor Variables For each component, we determined its task-relatedness using temporal sorting in GIFT, which utilizes the time-course of the component as the dependent variable, and variables from the design matrix of the task as independent variables.
53-1	9719-9727	Temporal	_
53-2	9728-9732	Sort	_
53-3	9733-9736	and	_
53-4	9737-9748	Development	_
53-5	9749-9751	of	_
53-6	9752-9755	the	_
53-7	9756-9765	Component	_
53-8	9766-9775	Predictor	_
53-9	9776-9785	Variables	_
53-10	9786-9789	For	_
53-11	9790-9794	each	_
53-12	9795-9804	component	_
53-13	9805-9806	,	_
53-14	9807-9809	we	_
53-15	9810-9820	determined	_
53-16	9821-9824	its	_
53-17	9825-9841	task-relatedness	_
53-18	9842-9847	using	_
53-19	9848-9856	temporal	_
53-20	9857-9864	sorting	_
53-21	9865-9867	in	_
53-22	9868-9872	GIFT	_
53-23	9873-9874	,	_
53-24	9875-9880	which	_
53-25	9881-9889	utilizes	_
53-26	9890-9893	the	_
53-27	9894-9905	time-course	_
53-28	9906-9908	of	_
53-29	9909-9912	the	_
53-30	9913-9922	component	_
53-31	9923-9925	as	_
53-32	9926-9929	the	_
53-33	9930-9939	dependent	_
53-34	9940-9948	variable	_
53-35	9949-9950	,	_
53-36	9951-9954	and	_
53-37	9955-9964	variables	_
53-38	9965-9969	from	_
53-39	9970-9973	the	_
53-40	9974-9980	design	_
53-41	9981-9987	matrix	_
53-42	9988-9990	of	_
53-43	9991-9994	the	_
53-44	9995-9999	task	_
53-45	10000-10002	as	_
53-46	10003-10014	independent	_
53-47	10015-10024	variables	_
53-48	10025-10026	.	_

Text=Food cues, smoking cues, and a constant were modeled which produced betas associated with each of the regressors.
54-1	10027-10031	Food	_
54-2	10032-10036	cues	_
54-3	10037-10038	,	_
54-4	10039-10046	smoking	_
54-5	10047-10051	cues	_
54-6	10052-10053	,	_
54-7	10054-10057	and	_
54-8	10058-10059	a	_
54-9	10060-10068	constant	_
54-10	10069-10073	were	_
54-11	10074-10081	modeled	_
54-12	10082-10087	which	_
54-13	10088-10096	produced	_
54-14	10097-10102	betas	_
54-15	10103-10113	associated	_
54-16	10114-10118	with	_
54-17	10119-10123	each	_
54-18	10124-10126	of	_
54-19	10127-10130	the	_
54-20	10131-10141	regressors	_
54-21	10142-10143	.	_

Text=These betas are similar to those one would see from a typical voxelwise GLM analysis such as those performed in previous work with the same task, except that the betas represent the degree to which the condition of interest is associated with increases/decreases in network activity rather than individual voxel activity.
55-1	10144-10149	These	_
55-2	10150-10155	betas	_
55-3	10156-10159	are	_
55-4	10160-10167	similar	_
55-5	10168-10170	to	_
55-6	10171-10176	those	_
55-7	10177-10180	one	_
55-8	10181-10186	would	_
55-9	10187-10190	see	_
55-10	10191-10195	from	_
55-11	10196-10197	a	_
55-12	10198-10205	typical	_
55-13	10206-10215	voxelwise	_
55-14	10216-10219	GLM	_
55-15	10220-10228	analysis	_
55-16	10229-10233	such	_
55-17	10234-10236	as	_
55-18	10237-10242	those	_
55-19	10243-10252	performed	_
55-20	10253-10255	in	_
55-21	10256-10264	previous	_
55-22	10265-10269	work	_
55-23	10270-10274	with	_
55-24	10275-10278	the	_
55-25	10279-10283	same	_
55-26	10284-10288	task	_
55-27	10289-10290	,	_
55-28	10291-10297	except	_
55-29	10298-10302	that	_
55-30	10303-10306	the	_
55-31	10307-10312	betas	_
55-32	10313-10322	represent	_
55-33	10323-10326	the	_
55-34	10327-10333	degree	_
55-35	10334-10336	to	_
55-36	10337-10342	which	_
55-37	10343-10346	the	_
55-38	10347-10356	condition	_
55-39	10357-10359	of	_
55-40	10360-10368	interest	_
55-41	10369-10371	is	_
55-42	10372-10382	associated	_
55-43	10383-10387	with	_
55-44	10388-10407	increases/decreases	_
55-45	10408-10410	in	_
55-46	10411-10418	network	_
55-47	10419-10427	activity	_
55-48	10428-10434	rather	_
55-49	10435-10439	than	_
55-50	10440-10450	individual	_
55-51	10451-10456	voxel	_
55-52	10457-10465	activity	_
55-53	10466-10467	.	_

Text=Similar analyses were performed for the ECN, SN and bilateral cuneus (negative control).
56-1	10468-10475	Similar	_
56-2	10476-10484	analyses	_
56-3	10485-10489	were	_
56-4	10490-10499	performed	_
56-5	10500-10503	for	_
56-6	10504-10507	the	_
56-7	10508-10511	ECN	_
56-8	10512-10513	,	_
56-9	10514-10516	SN	_
56-10	10517-10520	and	_
56-11	10521-10530	bilateral	_
56-12	10531-10537	cuneus	_
56-13	10538-10539	(	_
56-14	10540-10548	negative	_
56-15	10549-10556	control	_
56-16	10557-10558	)	_
56-17	10559-10560	.	_

Text=Betas associated with smoke cues (Smoke) and food cues (Food) were extracted for each individual subject, and the difference between Smoke and Food was calculated (Smoke-Food).
57-1	10561-10566	Betas	_
57-2	10567-10577	associated	_
57-3	10578-10582	with	_
57-4	10583-10588	smoke	_
57-5	10589-10593	cues	_
57-6	10594-10595	(	_
57-7	10596-10601	Smoke	_
57-8	10602-10603	)	_
57-9	10604-10607	and	_
57-10	10608-10612	food	_
57-11	10613-10617	cues	_
57-12	10618-10619	(	_
57-13	10620-10624	Food	_
57-14	10625-10626	)	_
57-15	10627-10631	were	_
57-16	10632-10641	extracted	_
57-17	10642-10645	for	_
57-18	10646-10650	each	_
57-19	10651-10661	individual	_
57-20	10662-10669	subject	_
57-21	10670-10671	,	_
57-22	10672-10675	and	_
57-23	10676-10679	the	_
57-24	10680-10690	difference	_
57-25	10691-10698	between	_
57-26	10699-10704	Smoke	_
57-27	10705-10708	and	_
57-28	10709-10713	Food	_
57-29	10714-10717	was	_
57-30	10718-10728	calculated	_
57-31	10729-10730	(	_
57-32	10731-10741	Smoke-Food	_
57-33	10742-10743	)	_
57-34	10744-10745	.	_

Text=T tests were computed on the beta values corresponding to Food and Smoke to establish whether or not there was a difference between the networks ’ response to the two cue types.
58-1	10746-10747	T	_
58-2	10748-10753	tests	_
58-3	10754-10758	were	_
58-4	10759-10767	computed	_
58-5	10768-10770	on	_
58-6	10771-10774	the	_
58-7	10775-10779	beta	_
58-8	10780-10786	values	_
58-9	10787-10800	corresponding	_
58-10	10801-10803	to	_
58-11	10804-10808	Food	_
58-12	10809-10812	and	_
58-13	10813-10818	Smoke	_
58-14	10819-10821	to	_
58-15	10822-10831	establish	_
58-16	10832-10839	whether	_
58-17	10840-10842	or	_
58-18	10843-10846	not	_
58-19	10847-10852	there	_
58-20	10853-10856	was	_
58-21	10857-10858	a	_
58-22	10859-10869	difference	_
58-23	10870-10877	between	_
58-24	10878-10881	the	_
58-25	10882-10890	networks	_
58-26	10891-10892	’	_
58-27	10893-10901	response	_
58-28	10902-10904	to	_
58-29	10905-10908	the	_
58-30	10909-10912	two	_
58-31	10913-10916	cue	_
58-32	10917-10922	types	_
58-33	10923-10924	.	_

Text=Clinical Outcome Prediction Our outcome variables (NumCig 6 and 12 weeks) were count variables which appeared to have a Poisson distribution, but did not meet the assumption required for a Poisson distribution (mean equaling variance) so we chose a negative binomial with log link model to predict clinical outcomes in SPSS.
59-1	10925-10933	Clinical	_
59-2	10934-10941	Outcome	_
59-3	10942-10952	Prediction	_
59-4	10953-10956	Our	_
59-5	10957-10964	outcome	_
59-6	10965-10974	variables	_
59-7	10975-10976	(	_
59-8	10977-10983	NumCig	_
59-9	10984-10985	6	_
59-10	10986-10989	and	_
59-11	10990-10992	12	_
59-12	10993-10998	weeks	_
59-13	10999-11000	)	_
59-14	11001-11005	were	_
59-15	11006-11011	count	_
59-16	11012-11021	variables	_
59-17	11022-11027	which	_
59-18	11028-11036	appeared	_
59-19	11037-11039	to	_
59-20	11040-11044	have	_
59-21	11045-11046	a	_
59-22	11047-11054	Poisson	_
59-23	11055-11067	distribution	_
59-24	11068-11069	,	_
59-25	11070-11073	but	_
59-26	11074-11077	did	_
59-27	11078-11081	not	_
59-28	11082-11086	meet	_
59-29	11087-11090	the	_
59-30	11091-11101	assumption	_
59-31	11102-11110	required	_
59-32	11111-11114	for	_
59-33	11115-11116	a	_
59-34	11117-11124	Poisson	_
59-35	11125-11137	distribution	_
59-36	11138-11139	(	_
59-37	11140-11144	mean	_
59-38	11145-11153	equaling	_
59-39	11154-11162	variance	_
59-40	11163-11164	)	_
59-41	11165-11167	so	_
59-42	11168-11170	we	_
59-43	11171-11176	chose	_
59-44	11177-11178	a	_
59-45	11179-11187	negative	_
59-46	11188-11196	binomial	_
59-47	11197-11201	with	_
59-48	11202-11205	log	_
59-49	11206-11210	link	_
59-50	11211-11216	model	_
59-51	11217-11219	to	_
59-52	11220-11227	predict	_
59-53	11228-11236	clinical	_
59-54	11237-11245	outcomes	_
59-55	11246-11248	in	_
59-56	11249-11253	SPSS	_
59-57	11254-11255	.	_

Text=This is the model of choice when a dependent variable has many zero values, and it assumes over-dispersion.
60-1	11256-11260	This	_
60-2	11261-11263	is	_
60-3	11264-11267	the	_
60-4	11268-11273	model	_
60-5	11274-11276	of	_
60-6	11277-11283	choice	_
60-7	11284-11288	when	_
60-8	11289-11290	a	_
60-9	11291-11300	dependent	_
60-10	11301-11309	variable	_
60-11	11310-11313	has	_
60-12	11314-11318	many	_
60-13	11319-11323	zero	_
60-14	11324-11330	values	_
60-15	11331-11332	,	_
60-16	11333-11336	and	_
60-17	11337-11339	it	_
60-18	11340-11347	assumes	_
60-19	11348-11363	over-dispersion	_
60-20	11364-11365	.	_

Text=In order to test a repeated measures outcome comprised of correlated variables (smoking at 6 week and 12 weeks) we used generalized estimating equations (GEE) with a robust covariance estimation method and assigned time as a within-subjects variable, and smoking as our outcome variable, which outputs a single test for the relationship between predictor and smoking outcome incorporating both 6 week and 12 week smoking outcomes.
61-1	11366-11368	In	_
61-2	11369-11374	order	_
61-3	11375-11377	to	_
61-4	11378-11382	test	_
61-5	11383-11384	a	_
61-6	11385-11393	repeated	_
61-7	11394-11402	measures	_
61-8	11403-11410	outcome	_
61-9	11411-11420	comprised	_
61-10	11421-11423	of	_
61-11	11424-11434	correlated	_
61-12	11435-11444	variables	_
61-13	11445-11446	(	_
61-14	11447-11454	smoking	_
61-15	11455-11457	at	_
61-16	11458-11459	6	_
61-17	11460-11464	week	_
61-18	11465-11468	and	_
61-19	11469-11471	12	_
61-20	11472-11477	weeks	_
61-21	11478-11479	)	_
61-22	11480-11482	we	_
61-23	11483-11487	used	_
61-24	11488-11499	generalized	_
61-25	11500-11510	estimating	_
61-26	11511-11520	equations	_
61-27	11521-11522	(	_
61-28	11523-11526	GEE	_
61-29	11527-11528	)	_
61-30	11529-11533	with	_
61-31	11534-11535	a	_
61-32	11536-11542	robust	_
61-33	11543-11553	covariance	_
61-34	11554-11564	estimation	_
61-35	11565-11571	method	_
61-36	11572-11575	and	_
61-37	11576-11584	assigned	_
61-38	11585-11589	time	_
61-39	11590-11592	as	_
61-40	11593-11594	a	_
61-41	11595-11610	within-subjects	_
61-42	11611-11619	variable	_
61-43	11620-11621	,	_
61-44	11622-11625	and	_
61-45	11626-11633	smoking	_
61-46	11634-11636	as	_
61-47	11637-11640	our	_
61-48	11641-11648	outcome	_
61-49	11649-11657	variable	_
61-50	11658-11659	,	_
61-51	11660-11665	which	_
61-52	11666-11673	outputs	_
61-53	11674-11675	a	_
61-54	11676-11682	single	_
61-55	11683-11687	test	_
61-56	11688-11691	for	_
61-57	11692-11695	the	_
61-58	11696-11708	relationship	_
61-59	11709-11716	between	_
61-60	11717-11726	predictor	_
61-61	11727-11730	and	_
61-62	11731-11738	smoking	_
61-63	11739-11746	outcome	_
61-64	11747-11760	incorporating	_
61-65	11761-11765	both	_
61-66	11766-11767	6	_
61-67	11768-11772	week	_
61-68	11773-11776	and	_
61-69	11777-11779	12	_
61-70	11780-11784	week	_
61-71	11785-11792	smoking	_
61-72	11793-11801	outcomes	_
61-73	11802-11803	.	_

Text=Maximum likelihood estimation (MLE) was used to estimate the negative binomial dispersion parameters and correlation matrix representing within subjects dependencies was assigned as AR (1).
62-1	11804-11811	Maximum	_
62-2	11812-11822	likelihood	_
62-3	11823-11833	estimation	_
62-4	11834-11835	(	_
62-5	11836-11839	MLE	_
62-6	11840-11841	)	_
62-7	11842-11845	was	_
62-8	11846-11850	used	_
62-9	11851-11853	to	_
62-10	11854-11862	estimate	_
62-11	11863-11866	the	_
62-12	11867-11875	negative	_
62-13	11876-11884	binomial	_
62-14	11885-11895	dispersion	_
62-15	11896-11906	parameters	_
62-16	11907-11910	and	_
62-17	11911-11922	correlation	_
62-18	11923-11929	matrix	_
62-19	11930-11942	representing	_
62-20	11943-11949	within	_
62-21	11950-11958	subjects	_
62-22	11959-11971	dependencies	_
62-23	11972-11975	was	_
62-24	11976-11984	assigned	_
62-25	11985-11987	as	_
62-26	11988-11990	AR	_
62-27	11991-11992	(	_
62-28	11993-11994	1	_
62-29	11995-11996	)	_
62-30	11997-11998	.	_

Text=P values associated with the Wald Chi Square were used to test significance of predictors.
63-1	11999-12000	P	_
63-2	12001-12007	values	_
63-3	12008-12018	associated	_
63-4	12019-12023	with	_
63-5	12024-12027	the	_
63-6	12028-12032	Wald	_
63-7	12033-12036	Chi	_
63-8	12037-12043	Square	_
63-9	12044-12048	were	_
63-10	12049-12053	used	_
63-11	12054-12056	to	_
63-12	12057-12061	test	_
63-13	12062-12074	significance	_
63-14	12075-12077	of	_
63-15	12078-12088	predictors	_
63-16	12089-12090	.	_

Text=Given previous work highlighting the importance of comorbid psychiatric symptoms, age, dependence severity, longer duration of prior quit attempts, gender, presence or absence of current alcohol problems and impulsiveness in treatment success, we chose to include the following clinical predictors in our outcome prediction model: FTND, age, gender, BDI, BAI, BIQ, number of serious previous quit attempts, and AUDIT.
64-1	12091-12096	Given	_
64-2	12097-12105	previous	_
64-3	12106-12110	work	_
64-4	12111-12123	highlighting	_
64-5	12124-12127	the	_
64-6	12128-12138	importance	_
64-7	12139-12141	of	_
64-8	12142-12150	comorbid	_
64-9	12151-12162	psychiatric	_
64-10	12163-12171	symptoms	_
64-11	12172-12173	,	_
64-12	12174-12177	age	_
64-13	12178-12179	,	_
64-14	12180-12190	dependence	_
64-15	12191-12199	severity	_
64-16	12200-12201	,	_
64-17	12202-12208	longer	_
64-18	12209-12217	duration	_
64-19	12218-12220	of	_
64-20	12221-12226	prior	_
64-21	12227-12231	quit	_
64-22	12232-12240	attempts	_
64-23	12241-12242	,	_
64-24	12243-12249	gender	_
64-25	12250-12251	,	_
64-26	12252-12260	presence	_
64-27	12261-12263	or	_
64-28	12264-12271	absence	_
64-29	12272-12274	of	_
64-30	12275-12282	current	_
64-31	12283-12290	alcohol	_
64-32	12291-12299	problems	_
64-33	12300-12303	and	_
64-34	12304-12317	impulsiveness	_
64-35	12318-12320	in	_
64-36	12321-12330	treatment	_
64-37	12331-12338	success	_
64-38	12339-12340	,	_
64-39	12341-12343	we	_
64-40	12344-12349	chose	_
64-41	12350-12352	to	_
64-42	12353-12360	include	_
64-43	12361-12364	the	_
64-44	12365-12374	following	_
64-45	12375-12383	clinical	_
64-46	12384-12394	predictors	_
64-47	12395-12397	in	_
64-48	12398-12401	our	_
64-49	12402-12409	outcome	_
64-50	12410-12420	prediction	_
64-51	12421-12426	model	_
64-52	12427-12428	:	_
64-53	12429-12433	FTND	_
64-54	12434-12435	,	_
64-55	12436-12439	age	_
64-56	12440-12441	,	_
64-57	12442-12448	gender	_
64-58	12449-12450	,	_
64-59	12451-12454	BDI	_
64-60	12455-12456	,	_
64-61	12457-12460	BAI	_
64-62	12461-12462	,	_
64-63	12463-12466	BIQ	_
64-64	12467-12468	,	_
64-65	12469-12475	number	_
64-66	12476-12478	of	_
64-67	12479-12486	serious	_
64-68	12487-12495	previous	_
64-69	12496-12500	quit	_
64-70	12501-12509	attempts	_
64-71	12510-12511	,	_
64-72	12512-12515	and	_
64-73	12516-12521	AUDIT	_
64-74	12522-12523	.	_

Text=NumCig at screen (over the previous 60 days), RxGrp, baseline demographic and clinical predictors associated with outcome in previous work, the neuroimaging predictor (Smoke-Food), and an interaction term (Smoke-Food/Smoke/Food × RxGrp) were also entered as predictors, and NumCig at 6 and 12 weeks (over the previous 28 and 30 days respectively) as the predicted outcomes.
65-1	12524-12530	NumCig	_
65-2	12531-12533	at	_
65-3	12534-12540	screen	_
65-4	12541-12542	(	_
65-5	12543-12547	over	_
65-6	12548-12551	the	_
65-7	12552-12560	previous	_
65-8	12561-12563	60	_
65-9	12564-12568	days	_
65-10	12569-12570	)	_
65-11	12571-12572	,	_
65-12	12573-12578	RxGrp	_
65-13	12579-12580	,	_
65-14	12581-12589	baseline	_
65-15	12590-12601	demographic	_
65-16	12602-12605	and	_
65-17	12606-12614	clinical	_
65-18	12615-12625	predictors	_
65-19	12626-12636	associated	_
65-20	12637-12641	with	_
65-21	12642-12649	outcome	_
65-22	12650-12652	in	_
65-23	12653-12661	previous	_
65-24	12662-12666	work	_
65-25	12667-12668	,	_
65-26	12669-12672	the	_
65-27	12673-12685	neuroimaging	_
65-28	12686-12695	predictor	_
65-29	12696-12697	(	_
65-30	12698-12708	Smoke-Food	_
65-31	12709-12710	)	_
65-32	12711-12712	,	_
65-33	12713-12716	and	_
65-34	12717-12719	an	_
65-35	12720-12731	interaction	_
65-36	12732-12736	term	_
65-37	12737-12738	(	_
65-38	12739-12760	Smoke-Food/Smoke/Food	_
65-39	12761-12762	×	_
65-40	12763-12768	RxGrp	_
65-41	12769-12770	)	_
65-42	12771-12775	were	_
65-43	12776-12780	also	_
65-44	12781-12788	entered	_
65-45	12789-12791	as	_
65-46	12792-12802	predictors	_
65-47	12803-12804	,	_
65-48	12805-12808	and	_
65-49	12809-12815	NumCig	_
65-50	12816-12818	at	_
65-51	12819-12820	6	_
65-52	12821-12824	and	_
65-53	12825-12827	12	_
65-54	12828-12833	weeks	_
65-55	12834-12835	(	_
65-56	12836-12840	over	_
65-57	12841-12844	the	_
65-58	12845-12853	previous	_
65-59	12854-12856	28	_
65-60	12857-12860	and	_
65-61	12861-12863	30	_
65-62	12864-12868	days	_
65-63	12869-12881	respectively	_
65-64	12882-12883	)	_
65-65	12884-12886	as	_
65-66	12887-12890	the	_
65-67	12891-12900	predicted	_
65-68	12901-12909	outcomes	_
65-69	12910-12911	.	_

Text=When the interaction term was not significant, we reran the model without it.
66-1	12912-12916	When	_
66-2	12917-12920	the	_
66-3	12921-12932	interaction	_
66-4	12933-12937	term	_
66-5	12938-12941	was	_
66-6	12942-12945	not	_
66-7	12946-12957	significant	_
66-8	12958-12959	,	_
66-9	12960-12962	we	_
66-10	12963-12968	reran	_
66-11	12969-12972	the	_
66-12	12973-12978	model	_
66-13	12979-12986	without	_
66-14	12987-12989	it	_
66-15	12990-12991	.	_

Text=In addition, we also ran the same model that we ran using Smoke-Food but using Smoke or Food alone as the neuroimaging predictor variable.
67-1	12992-12994	In	_
67-2	12995-13003	addition	_
67-3	13004-13005	,	_
67-4	13006-13008	we	_
67-5	13009-13013	also	_
67-6	13014-13017	ran	_
67-7	13018-13021	the	_
67-8	13022-13026	same	_
67-9	13027-13032	model	_
67-10	13033-13037	that	_
67-11	13038-13040	we	_
67-12	13041-13044	ran	_
67-13	13045-13050	using	_
67-14	13051-13061	Smoke-Food	_
67-15	13062-13065	but	_
67-16	13066-13071	using	_
67-17	13072-13077	Smoke	_
67-18	13078-13080	or	_
67-19	13081-13085	Food	_
67-20	13086-13091	alone	_
67-21	13092-13094	as	_
67-22	13095-13098	the	_
67-23	13099-13111	neuroimaging	_
67-24	13112-13121	predictor	_
67-25	13122-13130	variable	_
67-26	13131-13132	.	_

Text=Additionally, we also ran the same models in the subset of individuals with complete data only.
68-1	13133-13145	Additionally	_
68-2	13146-13147	,	_
68-3	13148-13150	we	_
68-4	13151-13155	also	_
68-5	13156-13159	ran	_
68-6	13160-13163	the	_
68-7	13164-13168	same	_
68-8	13169-13175	models	_
68-9	13176-13178	in	_
68-10	13179-13182	the	_
68-11	13183-13189	subset	_
68-12	13190-13192	of	_
68-13	13193-13204	individuals	_
68-14	13205-13209	with	_
68-15	13210-13218	complete	_
68-16	13219-13223	data	_
68-17	13224-13228	only	_
68-18	13229-13230	.	_

Text=Finally, we reran the models with fewer (only the essential) covariates.
69-1	13231-13238	Finally	_
69-2	13239-13240	,	_
69-3	13241-13243	we	_
69-4	13244-13249	reran	_
69-5	13250-13253	the	_
69-6	13254-13260	models	_
69-7	13261-13265	with	_
69-8	13266-13271	fewer	_
69-9	13272-13273	(	_
69-10	13274-13278	only	_
69-11	13279-13282	the	_
69-12	13283-13292	essential	_
69-13	13293-13294	)	_
69-14	13295-13305	covariates	_
69-15	13306-13307	.	_

Text=Finally, we used independent samples t-tests to compare the values for Smoke-Food, Smoke, and Food between abstinent and non-abstinent individuals at 6 and 12 weeks respectively, results for which are summarized in Table 6,7, S1–3.
70-1	13308-13315	Finally	_
70-2	13316-13317	,	_
70-3	13318-13320	we	_
70-4	13321-13325	used	_
70-5	13326-13337	independent	_
70-6	13338-13345	samples	_
70-7	13346-13353	t-tests	_
70-8	13354-13356	to	_
70-9	13357-13364	compare	_
70-10	13365-13368	the	_
70-11	13369-13375	values	_
70-12	13376-13379	for	_
70-13	13380-13390	Smoke-Food	_
70-14	13391-13392	,	_
70-15	13393-13398	Smoke	_
70-16	13399-13400	,	_
70-17	13401-13404	and	_
70-18	13405-13409	Food	_
70-19	13410-13417	between	_
70-20	13418-13427	abstinent	_
70-21	13428-13431	and	_
70-22	13432-13445	non-abstinent	_
70-23	13446-13457	individuals	_
70-24	13458-13460	at	_
70-25	13461-13462	6	_
70-26	13463-13466	and	_
70-27	13467-13469	12	_
70-28	13470-13475	weeks	_
70-29	13476-13488	respectively	_
70-30	13489-13490	,	_
70-31	13491-13498	results	_
70-32	13499-13502	for	_
70-33	13503-13508	which	_
70-34	13509-13512	are	_
70-35	13513-13523	summarized	_
70-36	13524-13526	in	_
70-37	13527-13532	Table	_
70-38	13533-13536	6,7	_
70-39	13537-13538	,	_
70-40	13539-13543	S1–3	_
70-41	13544-13545	.	_

